Serum glial fibrillary acidic protein is related to focal @entity1545 and outcome after XXXX .

@entity1 @entity1545 @entity64 @entity548 @entity510 @entity75 @entity63 @entity538
BACKGROUND AND PURPOSE: @entity510 ( @entity510 ) stands out from other subtypes of @entity64 because of the high early mortality and the risk of complications. Serum glial fibrillary acidic protein (s- @entity538 ) concentrations are increased after @entity64 . The aim of this study was to investigate whether s- @entity538 could be used as a marker of @entity75 and outcome after @entity510 . METHODS: Serum samples were obtained on a regular basis from 116 adults during a 2-week period after @entity510 and analyzed using an enzyme-linked immunosorbent assay. The World Federation of Neurological Surgeons scale was used for neurological evaluation. Outcome was assessed after 1 year and categorized according to the Extended Glasgow Outcome Scale. RESULTS: Increased s- @entity538 levels were seen in 81 of the 116 @entity1 . Maximum s- @entity538 correlated with World Federation of Neurological Surgeons scale on arrival and on days 10 to 15 (r=0.37, P<0.001 and r=0.47, P<0.001, respectively). Furthermore, maximum s- @entity538 levels were increased in the @entity1 group with radiological signs of focal lesions acute or at 1 year, compared with the group without focal lesions (P<0.001 in both comparisons). @entity1 with secondary events (re- @entity548 or @entity63 ) reached maximum levels later in the series and both maximum and final s- @entity538 levels increased compared with the levels in @entity1 without secondary events (P<0.001 in all 3 comparisons). Finally, maximum s- @entity538 correlated with outcome (r=-0.48, P<0.001) and s- @entity538 was an independent predictor of dichotomized outcome. CONCLUSIONS: s- @entity538 provides information about @entity1545 severity and outcome after @entity510 , which can be useful as a complement to clinical data.
